Category
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Today's News
More News
AFM24 Plus Atezolizumab Shows Acceptable Safety, Early Activity in EGFR+ Solid Tumors

AFM24 Plus Atezolizumab Shows Acceptable Safety, Early Activity in EGFR+ Solid Tumors

January 14, 2023Ryan ScottA doublet comprised of the bispecific innate cell engager AFM24 and atezolizumab had a tolerable safety profile and elicited responses in patients with advanced EGFR-expressi

AFM24 Plus Atezolizumab Shows Acceptable Safety, Early Activity in EGFR+ Solid Tumors

January 14, 2023Ryan ScottA doublet comprised of the bispecific innate cell engager AFM24 and atezolizumab had a tolerable safety profile and elicited responses in patients with advanced EGFR-expressi
AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

January 13, 2023Chris RyanMoxetumomab pasudotox-tdfk will be permanently discontinued in the United States market for the treatment of relapsed/refractory hairy cell leukemia.Hairy Cell Leukemia (Kate

AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

January 13, 2023Chris RyanMoxetumomab pasudotox-tdfk will be permanently discontinued in the United States market for the treatment of relapsed/refractory hairy cell leukemia.Hairy Cell Leukemia (Kate
Fox Chase Physician Wins Best Poster Award at Breast Cancer Meeting for Research on Surgery to

Fox Chase Physician Wins Best Poster Award at Breast Cancer Meeting for Research on Surgery to

May 26, 2023Fox Chase Cancer CenterAustin D. Williams, MD, MSEd, of Fox Chase Cancer Center, received the Best Poster Award at the recent 24th Annual Meeting of the American Society of Breast Surgeons

Fox Chase Physician Wins Best Poster Award at Breast Cancer Meeting for Research on Surgery to

May 26, 2023Fox Chase Cancer CenterAustin D. Williams, MD, MSEd, of Fox Chase Cancer Center, received the Best Poster Award at the recent 24th Annual Meeting of the American Society of Breast Surgeons
Enfortumab Vedotin Plus Pembrolizumab Generates Survival Benefit in Previously Untreated

Enfortumab Vedotin Plus Pembrolizumab Generates Survival Benefit in Previously Untreated

September 22, 2023Chris RyanTreatment with the combination of enfortumab Vedotin and pembrolizumab led to an improvement in overall survival and progression-free survival compared with chemotherapy in

Enfortumab Vedotin Plus Pembrolizumab Generates Survival Benefit in Previously Untreated

September 22, 2023Chris RyanTreatment with the combination of enfortumab Vedotin and pembrolizumab led to an improvement in overall survival and progression-free survival compared with chemotherapy in
Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter Transformation

Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter Transformation

June 23, 2023Ryan ScottThe combination of venetoclax, atezolizumab, and obinutuzumab elicited responses and prolonged time progression, in patients with chronic lymphocytic leukemia with Richter trans

Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter Transformation

June 23, 2023Ryan ScottThe combination of venetoclax, atezolizumab, and obinutuzumab elicited responses and prolonged time progression, in patients with chronic lymphocytic leukemia with Richter trans
Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho
Lutetium Lu 177 Vipivotide Tetraxetan Provides HRQOL Benefit, Reduces Skeletal Events in mCRPC

Lutetium Lu 177 Vipivotide Tetraxetan Provides HRQOL Benefit, Reduces Skeletal Events in mCRPC

July 9, 2023Kyle DohertyThe addition of lutetium Lu 177 vipivotide tetraxetan to standard-of-care treatment delayed time to worsening of health-related quality of life and skeletal events compared wit

Lutetium Lu 177 Vipivotide Tetraxetan Provides HRQOL Benefit, Reduces Skeletal Events in mCRPC

July 9, 2023Kyle DohertyThe addition of lutetium Lu 177 vipivotide tetraxetan to standard-of-care treatment delayed time to worsening of health-related quality of life and skeletal events compared wit
ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17, 2023Ashling WahnerPatients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17, 2023Ashling WahnerPatients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic
Adjuvant Nivolumab Receives CHMP Recommendation for Completely Resected Stage IIB/C Melanoma

Adjuvant Nivolumab Receives CHMP Recommendation for Completely Resected Stage IIB/C Melanoma

July 21, 2023Chris RyanThe European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of nivolumab monotherapy for the adjuvant treatment of patients at least

Adjuvant Nivolumab Receives CHMP Recommendation for Completely Resected Stage IIB/C Melanoma

July 21, 2023Chris RyanThe European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of nivolumab monotherapy for the adjuvant treatment of patients at least
Oncolytic Virus Enables the Immune System to Attack Tumors

Oncolytic Virus Enables the Immune System to Attack Tumors

by Shana SpindlerOne of the most important findings in cancer research in the past two decades is that tumors can create force field-like protection against the immune system. A new study has identifi

Oncolytic Virus Enables the Immune System to Attack Tumors

by Shana SpindlerOne of the most important findings in cancer research in the past two decades is that tumors can create force field-like protection against the immune system. A new study has identifi
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...